admin, Autor Laurent Pharma

Laurent Pharmaceuticals presents data with LAU-7b in Idiopathic Pulmonary Fibrosis at the 2024 ATS International Conference

Post published:13 May 2024

Laurent Pharmaceuticals presents data with LAU-7b in Idiopathic Pulmonary Fibrosis at the 2024 ATS International Conference, May 17-22, San Diego, CA, USA

Laurent Pharma to participate to BIO International Convention

Post published:13 May 2024

Laurent Pharma to participate to BIO International Convention, June 3-6 2024, San Diego, CA, USA

Laurent Pharmaceuticals Receives Health Canada’s Approval to Initiate Phase 2/3 Clinical Trial in Long COVID

Post published:29 August 2023

The ESSOR study is a natural extension to our ongoing evaluation of LAU-7b as a next-generation COVID-19 therapeutic, which generated positive results in patients with acute COVID-19 infection and is…